
    
      The duration of the study for each patient will include an up to 28-day screening phase,
      21-day study treatment cycles, an end of treatment visit with a follow-up period. Each
      patient will participate in only one dose group and will receive AVE8062 with bevacizumab
      every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or
      Investigator's decision.
    
  